The New Zealand medical journal · 2014
Duodenal switch--the initial experience in New Zealand.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Humphreys Martyn L, Robinson Steven J, McKeand Caryne, Hammodat Hisham
Аннотация
AIMS: The duodenal switch (DS) has now established itself as an effective, durable and safe bariatric procedure. We present our initial experience on 60 patients from May 2008 to November 2012.
METHODS: Retrospective case series from a prospective database. 94.8% follow-up over 4 years.
RESULTS: 45 patients have completed 1-year follow-up and 28 patients completed 2-year follow-up. The mean initial body mass index (BMI) was 52.8 kg/m(2) (range 40=66 kg/m(2)). The excess weight loss has been 69.5% at 1 year (n=45) and 73.1% at 2 years (n=28) respectively. The mean hospital stay is 5.08 days (range 3-18). The range of bowel motions at 1 year is one to two movements per day. Comorbidity resolution rates were 95% (n=18) for diabetes, 100% (n=9) for obstructive sleep apnoea, 72% (18/25) or hypertension, and 92% (33/36) or dyslipidaemia. One death from liver failure occurred 9 months following surgery resulting from poor compliance with follow-up and intake of multivitamins.
CONCLUSION: In our short-term analysis DS appears to be very efficient in terms of cure rate for morbid obesity and its comorbidities. In terms of risk/benefit DS has appeared safe with adherence to the appropriate follow-up regimen.
METHODS: Retrospective case series from a prospective database. 94.8% follow-up over 4 years.
RESULTS: 45 patients have completed 1-year follow-up and 28 patients completed 2-year follow-up. The mean initial body mass index (BMI) was 52.8 kg/m(2) (range 40=66 kg/m(2)). The excess weight loss has been 69.5% at 1 year (n=45) and 73.1% at 2 years (n=28) respectively. The mean hospital stay is 5.08 days (range 3-18). The range of bowel motions at 1 year is one to two movements per day. Comorbidity resolution rates were 95% (n=18) for diabetes, 100% (n=9) for obstructive sleep apnoea, 72% (18/25) or hypertension, and 92% (33/36) or dyslipidaemia. One death from liver failure occurred 9 months following surgery resulting from poor compliance with follow-up and intake of multivitamins.
CONCLUSION: In our short-term analysis DS appears to be very efficient in terms of cure rate for morbid obesity and its comorbidities. In terms of risk/benefit DS has appeared safe with adherence to the appropriate follow-up regimen.